ADIL DAUD, MD
Osteopathic Medicine at Usf Magnolia Dr, Tampa, FL
License number
Florida ME85033
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Florida ME85033
Category
Osteopathic Medicine
Type
Hematology
License number
Florida ME85033
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
2
12902 Usf Magnolia Dr, Tampa, FL 33612
PO Box 917770, Orlando, FL 32891
PO Box 917770, Orlando, FL 32891
Phone
(813) 972-8414
(813) 979-7211 (Fax)
(813) 979-7211 (Fax)
Personal information
See more information about ADIL DAUD at radaris.comName
Address
Phone
6539 Stonington Dr S, Tampa, FL 33647
Organization information
See more information about ADIL DAUD at bizstanding.comAdil Daud MD
12902 Usf Magnolia Dr, Tampa, FL 33612
Industry:
Internist
Phone:
(813) 972-8414 (Phone)
Adil Iqbal Daud
Professional information
Adil Iqbal Daud, Tampa FL
Specialties:
Internal Medicine, Hematology, Medical Oncology
Work:
H Lee Moffitt Cancer Ctr
12902 Usf Magnolia Dr, Tampa, FL 33612
12902 Usf Magnolia Dr, Tampa, FL 33612
Education:
Government Medical College, Nagpur (1986)
Adil Iqbal Daud, Tampa FL
Specialties:
Oncologist
Address:
12902 Usf Magnolia Dr, Tampa, FL 33612
Education:
Doctor of Medicine
Adil Daud
Location:
Tampa/St. Petersburg, Florida Area
Industry:
Medical Practice
Method Of Predicting Non-Response To First Line Chemotherapy
US Patent:
2010018, Jul 22, 2010
Filed:
Jan 11, 2010
Appl. No.:
12/685367
Inventors:
Timothy J. Yeatman - Thonotosassa FL, US
Deepak Agrawal - Tampa FL, US
Adil Daud - Tampa FL, US
Deepak Agrawal - Tampa FL, US
Adil Daud - Tampa FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The invention provides a method for determining a prognosis of colorectal cancer in a colorectal cancer patient, comprising classifying said patient as having a good prognosis or a poor prognosis using measurements of a plurality of gene products in a cell sample taken from said patient, said gene products being respectively products of at least 1 of the genes listed in Table 1, or respective functional equivalents thereof, wherein said good prognosis predicts a positive response to standard chemotherapy regimens, and said poor prognosis predicts non-responsiveness. Provided herein, the invention includes a gene signature to predict which patients will to benefit from standard colon cancer therapy; alternatively, patients who are classified as non-responders may be more likely to benefit from a novel agent such as a Notch inhibitor.